ArticleJournal of cachexia, sarcopenia and muscle2026
ALNCR.TNM as a Novel Prognostic Tool for Cancer Survival.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSystemic inflammation is associated with cancer prognosis, but commonly used inflammatory indices show limited discrimination across heterogeneous malignancies. We developed and validated a novel inflammatory burden index, ALNCR, and tested whether integrating ALNCR with TNM stage improves overall survival (OS) prediction.
methodsWe analysed 6374 adults with cancer from the multicentre INSCOC cohort (2013-2021), randomly split into a training cohort (n = 4464) and internal validation cohort (n = 1910), and an external validation cohort from Fujian Cancer Hospital (n = 759). Female proportions were 39.0%, 41.2% and 32.0%, and median ages were 60, 60 and 58 years, respectively; Stage IV disease accounted for 45.4%, 45.8% and 64.8%. ALNCR was defined as (albumin × lymphocyte) / (neutrophil × C-reactive protein). Discrimination was assessed using C-index and time-dependent AUC, with comparisons to NLR, PLR, CAR, SII and PNI. A combined model (ALNCR.TNM) used ALNCR (cutoff 3.21) and TNM stage (I/II vs. III/IV); incremental value was quantified by net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
resultsALNCR showed the highest discrimination for OS among evaluated indices (C-index 0.645 [95% CI 0.631-0.658] in training; 0.666 [0.645-0.686] in internal validation; and 0.657 [0.624-0.690] in external validation). High ALNCR (≥ 3.21) was associated with longer OS than low ALNCR (median OS not reached vs. 22.3 months; log-rank p < 0.001). After multivariable adjustment, high ALNCR remained associated with lower mortality (HR 0.56 [0.51-0.61], 0.50 [0.43-0.58] and 0.53 [0.42-0.67] across the three cohorts; all p < 0.001). Adding ALNCR to TNM improved prediction over TNM alone (ΔC-index +0.021; NRI 0.067, p = 0.010; IDI 0.004, p < 0.001) and stratified patients into four risk groups (p < 0.0001), with consistent associations across major cancer types and clinical strata.
conclusionsALNCR is a simple inflammation-based prognostic index that outperforms conventional inflammatory markers for OS prediction. Integrating ALNCR with TNM stage improves risk stratification and prognostic accuracy, supporting clinical implementation via a nomogram and web-based calculator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.